Interestingly, in treatment-naive and second-line patients with DLBCL, Immunosign 21 did correlate with myeloid subsets (macrophage density, P = 0.0077, and CD68 gene expression, P = 5.5 × 10−15, respectively; Extended Data Fig. 6c,d), in addition to CD8 T cells. This evidence concerns the gene CD8A and diffuse large B-cell lymphoma.